Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii

Hospitales Universitarios Virgen del Rocío67 enrolled

Overview

Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Cross Infection Pneumonia, Bacterial

Interventions

ColistinDRUG

intravenous colistin and nebulized colistin

Colistin and saline solutionDRUG

intravenous colistin and nebulized saline solution

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnose of VAP due A. baumannii or A. baumannii and another microorganism carbapenems resistant. * Clinical Pulmonary Infection Score (CPIS) \> 6 Exclusion Criteria: * Allergy to colistin. * Asthma * Shock status * Diagnose of VAP due A. baumannii colistin resistant.

Locations (1)

Hospital Universitario Virgen del Rocío

Seville, Seville, Spain

RECRUITING

Outcomes

Primary Outcomes

Time frame: 14 days

Central Contacts

José Garnacho, MD

CONTACT

34-95-501-2235 jose.garnacho.sspa@juntadeandalucia.es

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.